Labeling cells for in vivo tracking using 19F MRI

Biomaterials

Volumn 33, Issue 34, 2012, Pages 8830-8840

  Srinivas, Mangala ^a   Boehm Sturm, Philipp ^b   Figdor, Carl G ^a   de Vries, I Jolanda ^a   Hoehn, Mathias ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

19F MRI; Cell therapy; Cell tracking; In vivo imaging; Perfluorocarbons

Indexed keywords

AUTOIMMUNE DISEASE; CELL IMAGING; CELL LOADING; CELL NUMBER; CELL THERAPY; CELL TRACKING; CELLULAR THERAPEUTICS; CLINICAL APPLICATION; CLINICAL USE; CURRENT CELLS; DENDRITIC CELLS; HUMAN CELLS; IMAGE DATA; IMMUNE CELLS; IN-VIVO; IN-VIVO IMAGING; LONGITUDINAL DATA; PERFLUOROCARBONS; TRANSPLANT REJECTION; TRANSPLANTED CELLS;

DATA HANDLING; ISOTOPES; STEM CELLS;

CYTOLOGY;

BLOOD SUBSTITUTE; FLUOROCARBON; PERFLUORO 15 CROWN ETHER; PERFLUOROOCTYL BROMIDE; PERFLUOROPOLYETHER; PHOSPHOLIPID; POLOXAMER; SURFACTANT; UNCLASSIFIED DRUG;

CELL COUNT; CELL FUNCTION; CELL LABELING; CELL TRACKING; CELL VIABILITY; CLEARANCE; COVALENT BOND; DENDRITIC CELL; EMULSION; ENZYME ACTIVITY; EX VIVO STUDY; FLUORINE NUCLEAR MAGNETIC RESONANCE; IMAGE PROCESSING; IMAGE RECONSTRUCTION; IN VIVO CELL TRACKING; MACROPHAGE; MICROFLUIDICS; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN BINDING; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS;

ANIMALS; CELL TRACKING; FLUORINE; FLUOROCARBONS; HUMANS; MAGNETIC RESONANCE IMAGING; STAINING AND LABELING;

ANIMALIA;

EID: 84866867269     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.08.048     Document Type: Review

References (112)

1. Srinivas M., Aarntzen E.H., Bulte J.W., Oyen W.J., Heerschap A., de Vries I.J., et al. Imaging of cellular therapies. Adv Drug Deliv Rev 2010, 62(11):1080-1093.
2. 19F MRI for quantitative in vivo cell tracking. Trends Biotechnol 2010, 28(7):363-370.
3. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008, 130(2):98-106.
4. Srinivas M., Cruz L.J., Bonetto F., Heerschap A., Figdor C.G., de Vries I.J. Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials 2010, 31(27):7070-7077.
5. Du W., Xu Z., Nystrom A.M., Zhang K., Leonard J.R., Wooley K.L. 19F- and fluorescently labeled micelles as nanoscopic assemblies for chemotherapeutic delivery. Bioconjug Chem 2008, 19(12):2492-2498.
6. Maillard E, Juszczak MT, Langlois A, Kleiss C, Sencier M, Bietiger W, et al. Perfluorocarbon emulsions prevent hypoxia of pancreatic beta cells. Cell Transplant, in press.
7. Mizukami S., Takikawa R., Sugihara F., Hori Y., Tochio H., Walchli M., et al. Paramagnetic relaxation-based 19f MRI probe to detect protease activity. J Am Chem Soc 2008, 130(3):794-795.
8. Yu J., Ma Z., Li Y., Koeneman K.S., Liu L., Mason R.P. Synthesis and evaluation of a novel gene reporter molecule: detection of beta-galactosidase activity using 19F NMR of a fluorinated vitamin B6 conjugate+. Med Chem 2005, 1(3):255-262.
9. Takaoka Y., Sakamoto T., Tsukiji S., Narazaki M., Matsuda T., Tochio H., et al. Self-assembling nanoprobes that display off/on 19F nuclear magnetic resonance signals for protein detection and imaging. Nat Chem 2009, 1(7):557-561.
10. Godin B., Tasciotti E., Liu X., Serda R.E., Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 2011, 44(10):979-989.
11. Bulte J.W., Douglas T., Witwer B., Zhang S.C., Strable E., Lewis B.K., et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 2001, 19(12):1141-1147.
12. Liu Y., Zhang N. Gadolinium loaded nanoparticles in theranostic magnetic resonance imaging. Biomaterials 2012, 33(21):5363-5375.
13. Temme S., Bonner F., Schrader J., Flogel U. 19F magnetic resonance imaging of endogenous macrophages in inflammation. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012, 4(3):329-343.
14. Stoll G., Basse-Lüsebrink T., Weise G., Jakob P. Visualization of inflammation using (19) F-magnetic resonance imaging and perfluorocarbons. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012, 4(4):438-447.
15. Bible E., Dell'acqua F., Solanky B., Balducci A., Crapo P.M., Badylak S.F., et al. Non-invasive imaging of transplanted human neural stem cells and ECM scaffold remodeling in the stroke-damaged rat brain by (19)F- and diffusion-MRI. Biomaterials 2012, 33(10):2858-2871.
16. Boehm-Sturm P., Mengler L., Wecker S., Hoehn M., Kallur T. In vivo tracking of human neural stem cells with 19F magnetic resonance imaging. PLoS One 2011, 6(12):e29040.
17. Ruiz-Cabello J., Walczak P., Kedziorek D.A., Chacko V.P., Schmieder A.H., Wickline S.A., et al. In vivo " hot spot" MR imaging of neural stem cells using fluorinated nanoparticles. Magn Reson Med 2008, 60(6):1506-1511.
18. Kim T., Momin E., Choi J., Yuan K., Zaidi H., Kim J., et al. Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells. J Am Chem Soc 2011, 133(9):2955-2961.
19. Cromer Berman S.M., Walczak P., Bulte J.W. Tracking stem cells using magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011, 3(4):343-355.
20. Liu L, Ye Q, Wu Y, Hsieh WY, Chen CL, Shen HH, et al. Tracking T-cells in vivo with a new nano-sized MRI contrast agent. Nanomedicine, in press.
21. Waiczies H., Lepore S., Janitzek N., Hagen U., Seifert F., Ittermann B., et al. Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells. PLoS One 2011, 6(7):e21981.
22. Thorek D.L., Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials 2008, 29(26):3583-3590.
23. Cromer Berman SM, Kshitiz, Wang CJ, Orukari I, Levchenko A, Bulte JW, et al. Cell motility of neural stem cells is reduced after SPIO-labeling, which is mitigated after exocytosis. Magn Reson Med, in press.
24. Bonetto F., Srinivas M., Heerschap A., Mailliard R., Ahrens E.T., Figdor C.G., et al. A novel (19)F agent for detection and quantification of human dendritic cells using magnetic resonance imaging. Int J Cancer 2011, 129(2):365-373.
25. Jain A.K., Das M., Swarnakar N.K., Jain S. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Crit Rev Ther Drug Carrier Syst 2011, 28(1):1-45.
26. Luo R., Neu B., Venkatraman S.S. Surface functionalization of nanoparticles to control cell interactions and drug release. Small 2012, 8(16):2585-2594.
27. Huang D.M., Hsiao J.K., Chen Y.C., Chien L.Y., Yao M., Chen Y.K., et al. The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles. Biomaterials 2009, 30(22):3645-3651.
28. Mant A., Chinnery F., Elliott T., Williams A.P. The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen. Immunology 2012, 136(2):163-175.
29. Noveck R.J., Shannon E.J., Leese P.T., Shorr J.S., Flaim K.E., Keipert P.E., et al. Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. Anesth Analg 2000, 91(4):812-822.
30. Castro O., Nesbitt A.E., Lyles D. Effect of a perfluorocarbon emulsion (Fluosol-DA) on reticuloendothelial system clearance function. Am J Hematol 1984, 16(1):15-21.
31. Lutz J. Studies on RES function in rats and mice after different doses of fluosol. Prog Clin Biol Res 1983, 122:197-208.
32. Lutz J., Barthel U., Metzenauer P. Variation in toxicity of Escherichia coli endotoxin after treatment with perfluorated blood substitutes in mice. Circ Shock 1982, 9(2):99-106.
33. Lane T.A., Lamkin G.E. Paralysis of phagocyte migration due to an artificial blood substitute. Blood 1984, 64(2):400-405.
34. Lane T.A., Lamkin G.E. Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute. Blood 1986, 68(2):351-354.
35. Lutz J., Kettemann M., Racz I., Noth U. Several methods utilized for the assessment of biocompatibility of perfluorochemicals. Artif Cells Blood Substit Immobil Biotechnol 1995, 23(3):407-415.
36. Flaim S.F. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Substit Immobil Biotechnol 1994, 22(4):1043-1054.
37. Hitchens T.K., Ye Q., Eytan D.F., Janjic J.M., Ahrens E.T., Ho C. 19F MRI detection of acute allograft rejection with in vivo perfluorocarbon labeling of immune cells. Magn Reson Med 2011, 65(4):1144-1153.
38. Diou O., Tsapis N., Giraudeau C., Valette J., Gueutin C., Bourasset F., et al. Long-circulating perfluorooctyl bromide nanocapsules for tumor imaging by (19)FMRI. Biomaterials 2012, 33(22):5593-5602.
39. Keupp J., Rahmer J., Grasslin I., Mazurkewitz P.C., Schaeffter T., Lanza G.M., et al. Simultaneous dual-nuclei imaging for motion corrected detection and quantification of 19F imaging agents. Magn Reson Med 2011, 66(4):1116-1122.
40. Hahn T., Kozerke S., Schwizer W., Fried M., Boesiger P., Steingoetter A. Visualization and quantification of intestinal transit and motor function by real-time tracking of 19F labeled capsules in humans. Magn Reson Med 2011, 66(3):812-820.
41. Schwarz R., Kaspar A., Seelig J., Kunnecke B. Gastrointestinal transit times in mice and humans measured with 27Al and 19F nuclear magnetic resonance. Magn Reson Med 2002, 48(2):255-261.
42. Schreiber W.G., Markstaller K., Weiler N., Eberle B., Laukemper-Ostendorf S., Scholz A., et al. 19F-MRT of pulmonary ventilation in the breath-hold technic using SF6 gas. Rofo 2000, 172(6):500-503.
43. Wolf W., Presant C.A., Waluch V. 19F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev 2000, 41(1):55-74.
44. Wolf W., Albright M.J., Silver M.S., Weber H., Reichardt U., Sauer R. Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn Reson Imaging 1987, 5(3):165-169.
45. van Laarhoven H.W., Klomp D.W., Rijpkema M., Kamm Y.L., Wagener D.J., Barentsz J.O., et al. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed 2007, 20(2):128-140.
46. Ruiz-Cabello J., Barnett B.P., Bottomley P.A., Bulte J.W. Fluorine (19F) MRS and MRI in biomedicine. NMR Biomed 2011, 24(2):114-129.
47. Maki J., Masuda C., Morikawa S., Morita M., Inubushi T., Matsusue Y., et al. The MR tracking of transplanted ATDC5 cells using fluorinated poly L-lysine-CF3. Biomaterials 2007, 28(3):434-440.
48. Masuda C., Maki Z., Morikawa S., Morita M., Inubushi T., Matsusue Y., et al. MR tracking of transplanted glial cells using poly-L-lysine-CF3. Neurosci Res 2006, 56(2):224-228.
49. Neubauer A.M., Myerson J., Caruthers S.D., Hockett F.D., Winter P.M., Chen J., et al. Gadolinium-modulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn Reson Med 2008, 60(5):1066-1072.
50. Chalmers K.H., Botta M., Parker D. Strategies to enhance signal intensity with paramagnetic fluorine-labelled lanthanide complexes as probes for 19F magnetic resonance. Dalton Trans 2011, 40(4):904-913.
51. Bommerich U., Trantzschel T., Mulla-Osman S., Buntkowsky G., Bargon J., Bernarding J. Hyperpolarized 19F-MRI: parahydrogen-induced polarization and field variation enable 19F-MRI at low spin density. Phys Chem Chem Phys 2010, 12(35):10309-10312.
52. Barnett B.P., Ruiz-Cabello J., Hota P., Liddell R., Walczak P., Howland V., et al. Fluorocapsules for improved function, immunoprotection, and visualization of cellular therapeutics with MR, US, and CT imaging. Radiology 2011, 258(1):182-191.
53. Doty F.D., Entzminger G., Kulkarni J., Pamarthy K., Staab J.P. Radio frequency coil technology for small-animal MRI. NMR Biomed 2007, 20(3):304-325.
54. Waters E.A., Chen J., Yang X., Zhang H., Neumann R., Santeford A., et al. Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopy. Magn Reson Med 2008, 60(5):1232-1236.
55. Schmid F, Holtke C, Parker D, Faber C. Boosting. (19)F MRI-SNR efficient detection of paramagnetic contrast agents using ultrafast sequences. Magn Reson Med, in press.
56. Krems B., Bachert P., Zabel H.J., Lorenz W.J. F-19-(H-1) nuclear Overhauser effect and proton decoupling of 5-fluorouracil and alpha-fluoro-beta-alanine. J Magn Reson B 1995, 108(2):155-164.
57. Noth U., Jager L.J., Lutz J., Haase A. Fast 19F-NMR imaging in vivo using FLASH-MRI. Magn Reson Imaging 1994, 12(1):149-153.
58. Mason R.P., Bansal N., Babcock E.E., Nunnally R.L., Antich P.P. A novel editing technique for 19F MRI: molecule-specific imaging. Magn Reson Imaging 1990, 8(6):729-736.
59. Busse L.J., Pratt R.G., Thomas S.R. Deconvolution of chemical shift spectra in two- or three-dimensional [19F] MR Imaging. J Comput Assist Tomogr 1988, 12(5):824-835.
60. Kampf T., Fischer a, Basse-Lüsebrink T.C., Ladewig G., Breuer F., Stoll G., et al. Application of compressed sensing to in vivo 3D -19F CSI. J Magn Reson 2010, 207(2):262-273.
61. Flogel U., Ding Z., Hardung H., Jander S., Reichmann G., Jacoby C., et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 2008, 118(2):140-148.
62. Srinivas M., Morel P.A., Ernst L.A., Laidlaw D.H., Ahrens E.T. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn Reson Med 2007, 58(4):725-734.
63. Lee D., Marro K., Shankland E., Mathis M. Quantitative 19F imaging using inductively coupled reference signal injection. Magn Reson Med 2010, 63(3):570-573.
64. Koay C.G., Basser P.J. Analytically exact correction scheme for signal extraction from noisy magnitude MR signals. J Magn Reson 2006, 179(2):317-322.
65. Waiczies H, Lepore S, Millward JM, Purfürst B, Niendorf T, Waiczies S. 19F/1H MRI of brain inflammation in experimental autoimmune encephalomyelitis. International Society for Magnetic Resonance in Medicine, 20th Annual Meeting and Exhibition; Melbourne, Australia; 2012.
66. Boehm-Sturm P, Pracht ED, Aswendt M, Henn N, Hoehn M. B1 correction for quantitative in vivo 19F magnetic resonance imaging with surface coils. International Society for Magnetic Resonance in Medicine, 20th Annual Meeting and Exhibition; Melbourne, Australia; 2012.
67. Basse-Lüsebrink TC, Sturm VJF, Vilter A, Kampf T, Behr VC, Jakob PM. Fast, Indirect assessment of the 19F B1 profile by 1H Bloch-Siegert B1 mapping using double-resonant 1H/19F Coils. International Society for Magnetic Resonance in Medicine, 20th Annual Meeting and Exhibition; Melbourne, Australia; 2012.
68. Kadayakkara D.K., Janjic J.M., Pusateri L.K., Young W.B., Ahrens E.T. In vivo observation of intracellular oximetry in perfluorocarbon-labeled glioma cells and chemotherapeutic response in the CNS using fluorine-19 MRI. Magn Reson Med 2010, 64(5):1252-1259.
69. Kok M.B., de Vries A., Abdurrachim D., Prompers J.J., Grull H., Nicolay K., et al. Quantitative (1)H MRI, (19)F MRI, and (19)F MRS of cell-internalized perfluorocarbon paramagnetic nanoparticles. Contrast Media Mol Imaging 2011, 6(1):19-27.
70. Waters E.A., Chen J.J., Allen J.S., Zhang H.Y., Lanza G.M., Wickline S.A. Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson 2008, 10(1):43.
71. Southworth R., Kaneda M., Chen J., Zhang L., Zhang H., Yang X., et al. Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by 19F NMR of VCAM-1 targeted nanobeacons. Nanomedicine 2009, 5(3):359-367.
72. Morawski A.M., Winter P.M., Yu X., Fuhrhop R.W., Scott M.J., Hockett F., et al. Quantitative " magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. Magn Reson Med 2004, 52(6):1255-1262.
73. Kaneda M.M., Caruthers S., Lanza G.M., Wickline S.A. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng 2009, 37(10):1922-1933.
74. Keupp J, Schmieder AH, Williams TA, Allen JS, Wickline SA, Lanza GM, et al. Ultra-short echo time 19F/1H Imaging of gadolinium-free perfluoro-carbon nanoparticles: A robust method for in vivo angiogenesis imaging. International Society for Magnetic Resonance in Medicine, 19th Annual Meeting and Exhibition; Montreal, Canada; 2011.
75. Goette M.J., Schmieder A.H., Williams T.A., Allen J.S., Keupp J., Lanza G., et al. In vivo quantitative imaging of angiogenesis- targeted PFOB nanoparticles in a hypercholesterol rabbit model using 19 F-MRI with ultra-short echo time balanced SSFP. Proceedings of the Society for Cardiovascular Magnetic Resonance, 15th Annual Meeting; Nice, France 2012, 14(Suppl. 1):1-2.
76. Yu J.X., Kodibagkar V.D., Cui W., Mason R.P. 19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. Curr Med Chem 2005, 12(7):819-848.
77. Yu J.-X., Kodibagkar V.D., Hallac R.R., Liu L., Mason R.P. Dual 19F/1H MR gene reporter molecules for in vivo detection of beta-galactosidase. Bioconjug Chem 2012, 23(3):596-603.
78. Yu J.X., Kodibagkar V.D., Liu L., Mason R.P. A 19F-NMR approach using reporter molecule pairs to assess beta-galactosidase in human xenograft tumors in vivo. NMR Biomed 2008, 21(7):704-712.
79. Boehm-Sturm P, Aswendt M, Breucker L, Henn N, Mengler L, Adamczak J, et al. Imaging structure and function of stem cell grafts in the mouse brain by combining 19F magnetic resonance imaging with bioluminescence imaging. International Society for Magnetic Resonance in Medicine, 20th Annual Meeting and Exhibition; Melbourne, Australia; 2012.
80. Srinivas M., Turner M.S., Janjic J.M., Morel P.A., Laidlaw D.H., Ahrens E.T. In vivo cytometry of antigen-specific t cells using (19)F MRI. Magn Reson Med 2009, 62(3):747-753.
81. Ahrens E.T., Flores R., Xu H., Morel P.A. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol 2005, 23(8):983-987.
82. Partlow K.C., Chen J., Brant J.A., Neubauer A.M., Meyerrose T.E., Creer M.H., et al. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J 2007, 21(8):1647-1654.
83. Janjic J.M., Srinivas M., Kadayakkara D.K., Ahrens E.T. Self-delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection. J Am Chem Soc 2008, 130(9):2832-2841.
84. Morel P.A., Srinivas M., Turner M.S., Fuschiotti P., Munshi R., Bahar I., et al. Gene expression analysis of dendritic cells that prevent diabetes in NOD mice: analysis of chemokines and costimulatory molecules. J Leukoc Biol 2011, 90(3):539-550.
85. Malaisse W.J., Zhang Y., Louchami K., Sharma S., Dresselaers T., Himmelreich U., et al. (19)F-heptuloses as tools for the non-invasive imaging of GLUT2-expressing cells. Arch Biochem Biophys 2012, 517(2):138-143.
86. Lim Y.T., Cho M.Y., Kang J.H., Noh Y.W., Cho J.H., Hong K.S., et al. Perfluorodecalin/[InGaP/ZnS quantum dots] nanoemulsions as 19F MR/optical imaging nanoprobes for the labeling of phagocytic and nonphagocytic immune cells. Biomaterials 2010, 31(18):4964-4971.
87. Lanza G.M., Yu X., Winter P.M., Abendschein D.R., Karukstis K.K., Scott M.J., et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002, 106(22):2842-2847.
88. Zhou Z.X., Zhang B.G., Zhang H., Huang X.Z., Hu Y.L., Sun L., et al. Drug packaging and delivery using perfluorocarbon nanoparticles for targeted inhibition of vascular smooth muscle cells. Acta Pharmacol Sin 2009, 30(11):1577-1584.
89. Gorelikov I., Martin A.L., Seo M., Matsuura N. Silica-coated quantum dots for optical evaluation of perfluorocarbon droplet interactions with cells. Langmuir 2011, 27(24):15024-15033.
90. Barnett B.P., Ruiz-Cabello J., Hota P., Ouwerkerk R., Shamblott M.J., Lauzon C., et al. Use of perfluorocarbon nanoparticles for non-invasive multimodal cell tracking of human pancreatic islets. Contrast Media Mol Imaging 2011, 6(4):251-259.
91. Lim Y.T., Noh Y.W., Cho J.H., Han J.H., Choi B.S., Kwon J., et al. Multiplexed imaging of therapeutic cells with multispectrally encoded magnetofluorescent nanocomposite emulsions. J Am Chem Soc 2009, 131(47):17145-17154.
92. Bartusik D., Tomanek B. Detection of fluorine labeled herceptin using cellular (19)F MRI ex vivo. J Pharm Biomed Anal 2010, 51(4):894-900.
93. Bartusik D., Tomanek B. Application of 19F magnetic resonance to study the efficacy of fluorine labeled drugs in the three-dimensional cultured breast cancer cells. Arch Biochem Biophys 2010, 493(2):234-241.
94. Ahrens E.T., Young W.B., Xu H., Pusateri L.K. Rapid quantification of inflammation in tissue samples using perfluorocarbon emulsion and fluorine-19 nuclear magnetic resonance. Biotechniques 2011, 50(4):229-234.
95. Ebner B., Behm P., Jacoby C., Burghoff S., French B.A., Schrader J., et al. Early assessment of pulmonary inflammation by 19F MRI in vivo. Circ Cardiovasc Imaging 2010, 3(2):202-210.
96. Noth U., Morrissey S.P., Deichmann R., Jung S., Adolf H., Haase A., et al. Perfluoro-15-crown-5-ether labelled macrophages in adoptive transfer experimental allergic encephalomyelitis. Artif Cells Blood Substit Immobil Biotechnol 1997, 25(3):243-254.
97. Ikomi F., Hanna G., Schmid-Schonbein G.W. Intracellular and extracellular transport of perfluoro carbon emulsion from subcutaneous tissue to regional lymphatics. Artif Cells Blood Substit Immobil Biotechnol 1994, 22(4):1441-1447.
98. Kadayakkara D.K., Ranganathan S., Young W.B., Ahrens E.T. Assaying macrophage activity in a murine model of inflammatory bowel disease using fluorine-19 MRI. Lab Invest 2012, 92(4):636-645.
99. Bartusik D., Tomanek B., Lattova E., Perreault H., Tuszynski J., Fallone G. The efficacy of new colchicine derivatives and viability of the T-Lymphoblastoid cells in three-dimensional culture using 19F MRI and HPLC-UV ex vivo. Bioorg Chem 2009, 37(6):193-201.
100. Lee C.P., Payne G.S., Oregioni A., Ruddle R., Tan S., Raynaud F.I., et al. A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. Br J Cancer 2009, 101(11):1860-1868.
101. Seddon B.M., Payne G.S., Simmons L., Ruddle R., Grimshaw R., Tan S., et al. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res 2003, 9(14):5101-5112.
102. Procissi D., Claus F., Burgman P., Koziorowski J., Chapman J.D., Thakur S.B., et al. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res 2007, 13(12):3738-3747.
103. Cui W., Otten P., Li Y., Koeneman K.S., Yu J., Mason R.P. Novel NMR approach to assessing gene transfection: 4-fluoro-2-nitrophenyl-beta-D-galactopyranoside as a prototype reporter molecule for beta-galactosidase. Magn Reson Med 2004, 51(3):616-620.
104. Dingman S., Snyder-Leiby T., Mack D.J., Thomas R., Guo C. Enzymatic assay for perfluoro-tagged metabolites of l-DOPA using crude lysate from E. coli transformed with pKKAADCII. Appl Microbiol Biotechnol 2004, 64(4):556-559.
105. Hamstra D.A., Lee K.C., Tychewicz J.M., Schepkin V.D., Moffat B.A., Chen M., et al. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 2004, 10(5):916-928.
106. Kodibagkar V.D., Yu J., Liu L., Hetherington H.P., Mason R.P. Imaging beta-galactosidase activity using 19F chemical shift imaging of lacZ gene-reporter molecule 2-fluoro-4-nitrophenol-beta-D-galactopyranoside. Magn Reson Imaging 2006, 24(7):959-962.
107. Yu J., Mason R.P. Synthesis and characterization of novel lacZ gene reporter molecules: detection of beta-galactosidase activity by 19F nuclear magnetic resonance of polyglycosylated fluorinated vitamin B6. J Med Chem 2006, 49(6):1991-1999.
108. Liu L., Kodibagkar V.D., Yu J.X., Mason R.P. 19F-NMR detection of lacZ gene expression via the enzymic hydrolysis of 2-fluoro-4-nitrophenyl beta-D-galactopyranoside in vivo in PC3 prostate tumor xenografts in the mouse. FASEB J 2007, 21(9):2014-2019.
109. Matsushita H., Mizukami S., Mori Y., Sugihara F., Shirakawa M., Yoshioka Y., et al. (19) F MRI monitoring of gene expression in living cells through cell-surface beta-lactamase activity. Chembiochem 2012, 13(11):1579-1583.
110. Mancini L., Davies L., Friedlos F., Falck-Miniotis M., Dzik-Jurasz A.S., Springer C.J., et al. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy. NMR Biomed 2009, 22(5):561-566.
111. Presant C.A., Jacobson J., Wolf W., Waluch V., Weitz I.C., Macdonald J.S. Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. Invest New Drugs 2002, 20(4):369-376.
112. Bonetto F., Srinivas M., Weigelin B., Cruz L.J., Heerschap A., Friedl P., et al. A large-scale (19) F MRI-based cell migration assay to optimize cell therapy. NMR Biomed 2012, 25(9):1095-1103.